LAV Biosciences Fund V, L.P. 4
4 · Terns Pharmaceuticals, Inc. · Filed Nov 28, 2022
Insider Transaction Report
Form 4
LAV Biosciences Fund V, L.P.
10% Owner
Transactions
- Sale
Common Stock
2022-11-23$5.50/sh−1,000,000$5,500,000→ 405,583 total(indirect: See footnotes) - Sale
Common Stock
2022-11-23$5.50/sh−166,666$916,663→ 529,762 total(indirect: See footnotes) - Sale
Common Stock
2022-11-23$5.50/sh−333,334$1,833,337→ 1,059,523 total(indirect: See footnotes)
Holdings
- 1,286,698(indirect: See footnotes)
Common Stock
Footnotes (5)
- [F1]Shares held by LAV Biosciences Fund V, L.P.
- [F2]LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.
- [F3]Shares held by Hopewell Resources Holdings Limited.
- [F4]Shares held by Oriental Spring Venture Limited.
- [F5]Shares held by LAV Aqua Limited.